Raloxifene hydrochloride for breast cancer risk reduction in postmenopausal women

@article{Provinciali2016RaloxifeneHF,
  title={Raloxifene hydrochloride for breast cancer risk reduction in postmenopausal women},
  author={Nicoletta Provinciali and Chen S. Suen and Barbara K. Dunn and Andrea Decensi},
  journal={Expert Review of Clinical Pharmacology},
  year={2016},
  volume={9},
  pages={1263 - 1272}
}
ABSTRACT Introduction: Raloxifene is an estrogen receptor modulator which competes with estrogens for binding to the estrogen receptor. Based on the results of the STAR (Study of Tamoxifen And Raloxifene) trial, raloxifene has been approved by the U.S. Food and Drug Administration for the reduction of breast cancer (BC) risk in postmenopausal women at increased risk. Areas covered: This analysis reviews the activity of raloxifene and the clinical trials for non-BC indications which led to… 

Combined Raloxifene and Letrozole for Breast Cancer Patients.

Pharmacotherapy for schizophrenia in postmenopausal women

TLDR
Estrogen modulators may not help all symptoms of schizophrenia but are, nevertheless, relatively safe and, when used as adjuncts, help to keep antipsychotic doses low, thus reducing the side effect burden.

Chemoprevention : Using Drugs and Nutrients to Decrease Cancer Risk

TLDR
This review addresses selected areas that are central to the state-of-the-art of cancer prevention science, and focuses on active intervention with measures involving pharmaceutical and immunological agents.

Nuclear receptors: recent drug discovery for cancer therapies.

TLDR
This article overviews NR-based drug discovery in cancer and related resistance mechanisms, focusing on novel strategies for targeting well-established NR targets, including ERα, AR, the glucocorticoid receptor and the progesterone receptor, as well as opportunities to target other NRs that are attracting interest in immuno-oncology.

Drug repurposing for breast cancer therapy: Old weapon for new battle

Risk Assessment for Hereditary Breast and Ovarian Cancers

  • Biology
  • 2018
TLDR
Risk factors for hereditary breast and ovarian cancers include a family history with highly penetrant mutations in genes such as BRCA1 and BRCa2, moderately penetrant mutation in other genes, as well as more common genomic variants, including single nucleotide polymorphisms, associated with modest effect sizes.

SG_WP_Breast&Ovarian Cancers_FINAL8_PRINT.indd

  • Biology
  • 2017
TLDR
Risk factors for hereditary breast and ovarian cancers include a family history with highly penetrant mutations in genes such as BRCA1 and BRCa2, moderately penetrant mutation in other genes, as well as more common genomic variants, including single nucleotide polymorphisms, associated with modest effect sizes.

Transcription Factors in Cancer Development and Therapy

TLDR
A comprehensive overview of the TFs that play a central role in cancer progression, which could be potential therapeutic candidates for developing specific inhibitors, and the efforts made to target some of those TFs, including NRs.

References

SHOWING 1-10 OF 94 REFERENCES

Review on raloxifene: profile of a selective estrogen receptor modulator.

  • M. Heringa
  • Medicine, Biology
    International journal of clinical pharmacology and therapeutics
  • 2003
TLDR
It has been proven that raloxifene decreases levels of both bone formation markers and bone resorption markers in postmenopausal women and preserves the bone mineral density at most skeletal sites in these women.

Raloxifene: a selective estrogen receptor modulator.

Raloxifene is a selective estrogen receptor modulator that produces both estrogen-agonistic effects on bone and lipid metabolism and estrogen-antagonistic effects on uterine endometrium and breast

Clinical effects of raloxifene hydrochloride in women.

TLDR
Raloxifene is now available as an alternative to estrogen replacement therapy for women at risk for osteoporosis and is reviewed during the past two decades on the clinical effects of ralox ifene in women.

Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women.

TLDR
Raloxifene favorably alters biochemical markers of cardiovascular risk by decreasing LDL-C, fibrinogen, and lipoprotein(a), and by increasing HDL2-C without raising triglycerides.

The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation.

TLDR
Among postmenopausal women with osteoporosis, the risk of invasive breast cancer was decreased by 76% during 3 years of treatment with raloxifene, mainly in the United States and Europe.

Pharmacokinetics of raloxifene and its clinical application.

  • D. Hochner-Celnikier
  • Medicine, Biology
    European journal of obstetrics, gynecology, and reproductive biology
  • 1999

Lasofoxifene for the prevention and treatment of postmenopausal osteoporosis

  • E. Lewiecki
  • Medicine, Biology
    Therapeutics and clinical risk management
  • 2009
TLDR
Clinical trials show that lasofoxifene is generally well tolerated with mild to moderate adverse events that commonly resolve even with drug continuation, and it is approved for the treatment of postmenopausal women at increased risk for fracture in some countries and is in the regulatory review process in others.

Use of SERMs for treatment in postmenopausal women

Raloxifene use in clinical practice: efficacy and safety

TLDR
Based on its approved indications, it is appropriate to prescribe raloxifene to prevent or treat osteoporosis, as well as to reduce the risk of invasive breast cancer in PMW with osteoporeosis or at high risk of breast cancer.
...